Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Clinical trial NCT00510510 · COMPLETED
Trial details
- NCT number
- NCT00510510
- Sponsor
- Novartis
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-08-01
- Primary completion
- 2008-01-01
- Enrollment
- 281
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.